公开(公告)号：US20250064871A1

公开(公告)日：2025-02-27

申请号：US18728163

申请日：2023-01-18

Applicant: The Regents of The University of California

Inventor： Anahid Jewett

IPC: A61K35/745 ,  A61K31/198 ,  A61K31/337 ,  A61K31/4985 ,  A61K31/519 ,  A61K33/243 ,  A61K35/00 ,  A61K35/744 ,  A61K35/747 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00

Abstract: The present application relates to probiotic compositions comprising two or more bacterial strains selected from: Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles, Lactobacillus acidophilus, Lactobacillus plantarum, and Lactobacillus paracasei.

公开(公告)号：US20250032557A1

公开(公告)日：2025-01-30

申请号：US18698698

申请日：2022-10-19

Applicant: METACEN THERAPEUTICS CO., LTD

Inventor： Myung Sook Oh ,  Eugene Huh ,  Myoung Gyu Park ,  Hoon Sung Jeh

IPC: A61K35/744 ,  A61K35/00 ,  A61P25/16 ,  C12N1/20 ,  C12R1/01

Abstract: The present invention relates to a novel Weissella cibaria strain and a use thereof. The novel Weissella cibaria strain according to the present invention and a composition comprising the same have not only antimicrobial activity against Proteus mirabilis, but also protective ability against neurotoxicity-induced apoptosis of neurons, inhibition ability against aggregation of α-synuclein, and safety, and thus can be utilized as a pharmaceutical composition, a food composition, and an animal feed composition, which are excellent in prevention, amelioration, or treatment of neurodegenerative diseases.

公开(公告)号：US20250019446A1

公开(公告)日：2025-01-16

申请号：US18571538

申请日：2021-06-16

Applicant: SHANGHAI SINOBAY BIOTECHNOLOGY CO., LTD.

Inventor： Jianqing Xu ,  Xiaoyan Zhang ,  Xiangqing Ding ,  Qibin Liao

IPC: C07K16/28 ,  A61K35/00 ,  A61K39/00 ,  A61K45/06 ,  A61K47/68

Abstract: The present invention provides an antibody targeting an AXL protein or an antigen binding fragment thereof, and a preparation method therefor and use thereof. Further provided are an isolated polynucleotide encoding the antibody targeting the AXL protein or the antigen binding fragment thereof, and a vector comprising the isolated polynucleotide. The antibody targeting the AXL provided by the present invention can specifically bind to the AXL protein, can mediate ADCC to kill tumors, or have an anti-tumor effect as a target recognition domain of CART cells, and can be used for preventing or treating tumors, and hence it has a wide application prospect.

公开(公告)号：US20250009859A1

公开(公告)日：2025-01-09

申请号：US18292905

申请日：2022-07-20

Applicant: ASTON SCI. INC.

Inventor： Hun JUNG ,  Hyo Hyun PARK

IPC: A61K39/00 ,  A61K9/00 ,  A61K35/00

Abstract: The present invention relates to an HER2-ICD DNA vaccine composition. The vaccine composition according to the present invention can effectively inhibit growth of gastric cancer without serious side effects in an animal model transplanted with a human gastric cancer cell line that expresses HER2, and thus may be usefully used in treatment of gastric cancer.

公开(公告)号：US20250000914A1

公开(公告)日：2025-01-02

申请号：US18703170

申请日：2022-10-19

Applicant: RAISON, LLP

Inventor： Tony Hagen

IPC: A61K35/74 ,  A01H3/00 ,  A23K10/18 ,  A23K10/30 ,  A61K35/00 ,  C02F3/34 ,  C02F103/06 ,  C02F103/26 ,  C02F103/36 ,  C12P3/00 ,  H01M8/0606

Abstract: Disclosed herein are compositions and using said compositions in methods for increasing hydrogen in the rumen of ruminants, and in methods of increasing enteric hydrogen emissions in subjects, landfills and topsoil, in fermentation. Also disclosed herein are compositions and using said compositions in methods for increasing hydrogen production from wastewater.

公开(公告)号：US20240425563A1

公开(公告)日：2024-12-26

申请号：US18261483

申请日：2022-01-13

Applicant: Washington University

Inventor： Nathan Singh ,  Ju Fang Chang

IPC: C07K14/725 ,  A61K35/00 ,  C07K16/28

Abstract: Among the various aspects of the present disclosure is the provision of MHC-independent T cell receptor (miTCR) compositions and methods of making and using the same.

公开(公告)号：US20240424038A1

公开(公告)日：2024-12-26

申请号：US18273796

申请日：2022-02-10

Applicant: DIC Corporation

Inventor： Yasuyuki Imai ,  Yurino Koseki

IPC: A61K35/748 ,  A61K9/20 ,  A61K35/00

Abstract: When a tablet is formed from blue-green algae powder alone, there are problems such as a deteriorated tableting ratio due to breaking, cracking, and the like and collapse due to moisture absorption and the like. During the formation of a tablet, an excipient such as a sucrose fatty acid ester and dextrin, and a binder need to be added, but the tablet recently does not satisfy a preference of consumers who would like to avoid the additives. The inventors of the present invention have done intensive study to solve the problems, and as a result, found that a formulation with blue-green algae powder and α-linolenic acid improves the tableting ratio of a blue-green algae-containing tablet, and completed the present invention.

公开(公告)号：US12173315B2

公开(公告)日：2024-12-24

申请号：US17406212

申请日：2021-08-19

Applicant: Emory University

Inventor： Frances Eun-Hyung Lee ,  Ignacio Sanz ,  Doan Nguyen

IPC: C12N5/0781 ,  A61K35/00

Abstract: This disclosure relates to growth media and environments for in vitro culturing of cells that produce or are capable of producing antibodies. In certain embodiments, the media comprises IL-6, fibronectin, and typically a saccharide. In certain embodiments, the disclosure contemplates cell culture compositions comprising IL-6 and fibronectin that are derived from proteins secreted from mesenchymal stromal/stem cells (MSCs). In certain embodiments, the disclosure contemplates enclosures comprising culture compositions disclosed herein that are in ambient air or optionally in an environment wherein oxygen is absent or at a low concentration.

公开(公告)号：US20240398973A1

公开(公告)日：2024-12-05

申请号：US18808584

申请日：2024-08-19

Applicant: Eli Lilly and Company

Inventor： Michael James Bacica ,  Yiqing Feng ,  Donmienne Doen Mun Leung ,  Matthew D. Linnik ,  Adam Robert Mezo ,  James Thomas Parker ,  Purva Vivek Trivedi ,  Francisco Alcides Valenzuela ,  Jianghuai Xu

IPC: A61K47/68 ,  A61K35/00 ,  C07K16/32

Abstract: Engineered antibody compounds and conjugates thereof, are provided, said antibody compounds and conjugates thereof are useful as agents for cancer immunotherapy. Engineered antibody compounds may include one or more amino acid residue substitutions within the constant regions of the antibody engineered into a parental antibody. Amino acid residue substitutions may include substitution of cysteine or alanine.

公开(公告)号：US12156890B2

公开(公告)日：2024-12-03

申请号：US16077411

申请日：2017-02-10

Applicant: The Johns Hopkins University

Inventor： Thomas Hartung ,  David Pamies ,  Helena T. Hogberg

IPC: A61K35/00 ,  A61K35/30 ,  A61K38/41 ,  C12N5/00 ,  C12N5/074 ,  G01N33/50 ,  G01N33/58 ,  G01N33/68

Abstract: The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.